Acerus Pharmaceuticals (TSX:ASP) Total Assets : C$63.59 Mil (As of Sep. 2022)

View and export this data going back to 2009. Start your Free Trial

What is Acerus Pharmaceuticals Total Assets?

Acerus Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2022 was C$63.59 Mil.

Total Assets is connected with ROA %. Acerus Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2022 was -36.57%. Total Assets is also linked to Revenue through Asset Turnover. Acerus Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2022 was 0.02.

Acerus Pharmaceuticals Total Assets Historical Data

The historical data trend for Acerus Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals Total Assets Chart

Acerus Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Assets

Get a 7-Day Free Trial

28.42

22.61

20.33

21.75

12.36

Acerus Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Assets	Get a 7-Day Free Trial															14.38	12.36	60.48	58.17	63.59

Acerus Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Acerus Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Assets	=	Total Equity (A: Dec. 2021 )	+	Total Liabilities (A: Dec. 2021 )
	=	-33.298	+	45.652
	=	12.35

Acerus Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2022 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2022 )	+	Total Liabilities (Q: Sep. 2022 )
	=	-18.535	+	82.122
	=	63.59

Acerus Pharmaceuticals (TSX:ASP) Total Assets Explanation

Total Assets is connected with ROA %.

Acerus Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2022 is

ROA %	=	Net Income (Q: Sep. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Sep. 2022 ))	/ count )
	=	-22.264	/	( (58.17	+	63.587)	/ 2 )
	=	-22.264	/	60.8785
	=	-36.57 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Acerus Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2022 is

	Asset Turnover
=	Revenue (Q: Sep. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Sep. 2022 ))	/ count )
=	1.027	/	( (58.17	+	63.587)	/ 2 )
=	1.027	/	60.8785
=	0.02

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Acerus Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Acerus Pharmaceuticals (TSX:ASP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (TSX:ASP) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8

Website

https://www.aceruspharma.com

Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Executives

Norma Beauchamp	Director
Stephen Robert Gregory	Director
Edward Joseph Gudaitis	Director, Senior Officer